At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted ...
Wave Life Sciences shares plunged >50% after Phase 1 INLIGHT data for WVE-007 showed <1% placebo-adjusted weight loss at six ...
The company said the study involved participants with less fat than those typically enrolled in later-stage obesity studies and that it had expected the drug to have greater effec ...
RBC Capital Markets upgraded Wave Life Sciences (WAV) to outperform from sector perform, lauding the recent phase 1 results for siRNA obesity therapy WVE-007 as having a relatively quick ...
Wave Life Sciences (WVE) announced the submission of its first clinical trial application, CTA, for WVE-007 in obesity. WVE-007 is an investigational GalNAc-conjugated small interfering RNA, siRNA, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results